Wegovy subscription pricing expands across telehealth platforms.

Novo launched subscription-style pricing for Wegovy through telehealth partners, offering lower monthly rates for three-, six- and 12-month commitments; the program lists Wegovy at $249/month with a 12-month plan and mainly targets self-pay patients.

Novo has rolled out a subscription-style pricing program for its weight-loss drug Wegovy, offering lower monthly costs for patients who commit to three, six or 12 months. The offering is available through telehealth platforms such as Ro, Weight Watchers and LifeMD, with Hims & Hers and others noted as coming soon. Prices fall to as low as $249 per month for a 12-month commitment for both injection and pill formats, while shorter commitments carry higher monthly rates. The program is aimed mainly at self-pay patients, while insured patients may access other programs that can reduce out-of-pocket costs. Key details: - Novo announced subscription pricing options for Wegovy with three-, six- and 12-month commitments. - The program is available via telehealth partners including Ro, Weight Watchers and LifeMD, with additional platforms to be added. - Monthly prices can drop to $249 at a 12-month commitment for injections and pill versions, with higher rates for shorter terms. - The initiative is focused on self-pay patients; insured patients may still have alternative programs with lower copays. - Novo’s approach aims to standardize pricing across telehealth channels while avoiding broader list price cuts and to encourage longer treatment adherence. Summary: The move highlights that access, bundled care and pricing are increasingly important in competition for obesity treatments as telehealth platforms become distribution and engagement channels. Undetermined at this time.